MediWound Ltd. Stock News

New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD). Such investors are a

NEW YORK, June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).

Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid

Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar r

Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therap

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021

MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2021 Results - Earnings Call Transcript

MediWound is preparing for NexoBrid's PDUFA date that is scheduled in June of this year. If approved, NexoBrid will be entering a $200M TAM with numerous benefits over the standard-of-care.

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and

Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time

MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2020 Results - Earnings Call Transcript

MediWound (MDWD) delivered earnings and revenue surprises of 45.45% and 19.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021